Two Exciting Phoenix Q&As Coming Up! Genetics and Photobiomodulation

Whole genome sequencing (WGS) reads your entire DNA code rather than sampling common variants like consumer SNP tests. For APOE4 carriers, WGS matters because APOE status is just one of many genetic contributors to Alzheimer risk. WGS reveals protective and risk variants across the full genome including rare variants that consumer tests miss. MyNucleus founder Kian Sadeghi joined a Phoenix Q&A to discuss how WGS data can inform brain health, longevity, and personalized protocols. Existing raw data from providers like Sequencing.com can usually be uploaded and reinterpreted on newer platforms.

Neuronic uses 1070 nanometer near-infrared light delivered through wearable helmets to stimulate brain tissue without invasive procedures. The 1070 nm wavelength is selected because it penetrates the skull effectively and is absorbed by mitochondrial cytochrome c oxidase, boosting cellular energy production. Clinical research targets memory, focus, sleep, and neuroprotection, with ongoing trials in mild cognitive impairment, Alzheimer disease, and long-COVID brain fog. Chris Garvin of Neuronic joined a Phoenix Q&A to explain the evidence base, home versus clinic use, and custom program design.

The Phoenix Experiment is a planned APOE4-specific experimentation platform built in partnership with apoe4.info. It replaces individual guesswork with structured interventions tested by carriers themselves, generating real-world evidence for the community. Members follow a baseline, intervention, and retest protocol and contribute data so everyone benefits. Dr. Kevin Tran launched a 5-minute survey and offered 30-minute calls with himself or Dr. Emily Cole of apoe4.info to shape the feature set directly with future users rather than through traditional product development.